Deal Announcement

goetzpartners advised NORD Holding

goetzpartners advised NORD Holding and Zentrum Gesundheit on the acquisition of REALEYES

Due Diligence
Debt Advisory
Healthcare and Life Sciences
Transaction
Dezember 2021
Icon: flag-DEIcon: flag-DE

goetzpartners advised

NORD Holding with a

Commercial Due Diligence
Debt Advisory

on the acquisition of REALEYES

value not disclosed

Fortlane Partners advised NORD Holding and its portfolio company Zentrum Gesundheit with a Commercial Due Diligence ("CDD") and Debt Advisory services on the acquisition of REALEYES, a leading ophthalmology platform headquartered in Munich with a comprehensive treatment portfolio spanning from medical surgeries over refractive surgeries for eye vision correction to a broad range of conservative treatments.

Within a competitive process, Fortlane Partners could apply its strength towards a competitive edge during the whole process by making use of its integrated service offering. Through the combination of our dedicated Private Equity Consulting practice, with plenty of expertise in the German healthcare and ophthalmology market, as well as our Debt Advisory experts, we were able to provide a bankable Commercial Due Diligence report early on, taking into account the information requirements of our client and potential lenders. The CDD was tailored to the specific investment opportunity with analyses covering the company's medical staff structure, capabilities and reputation of surgeons, branch-by-branch financial performance, and a differentiated view on COVID-19-related effects on a per-treatment basis. The Debt Advisory team managed the competitive lender due diligence process with various potential financing structures, advised during the term sheet and credit contract negotiations, and ensured a swift financing process to achieve best market terms within a tight deadline. During the whole due diligence and Q&A process, the seamless and established collaboration of both teams ensured both, a smooth and fast-paced process as well as maximum transaction security.

The project is another successful example for Fortlane Partners’ unique service portfolio combining transaction-related services incl. Commercial Due Diligence, Debt Advisory, and M&A in the interest of its clients. For NORD Holding's Zentrum Gesundheit Group this transaction constitutes the eighth add-on investment in 2021.

About REALEYES
Founded in Germany in 2000 and headquartered in Munich, REALEYES is a market leader among premium providers of ophthalmology services with 126 employees at 21 sites. The network's comprehensive treatment portfolio spans from medical surgeries, especially comprising cataract and IVOM treatments, over refractive surgeries for eye vision correction to a broad range of other surgeries and conservative treatments.

About NORD Holding
With a more than 50-year history and assets under management of € 2.5 billion NORD Holding is one of the leading private equity asset management companies in Germany. The business consists of the Direct Investments and the Fund Investments divisions.

 

Transaction Team:

 

Commercial Due Diligence

 

Dr. Gerrit Schütte
Managing Director

Alexander Reitmann
Manager

Linh Dong
Consultant

Dominik Wenzel
Consultant

Debt Advisory

 

Philipp Widmaier
Managing Director

Marius Wolter
Associate Director

Weitere TransaktionenDas könnte Sie auch interessieren...

Dezember 2022
Icon: flag-CHIcon: flag-DE

goetzpartners advised

Deutsche Invest Capital Solutions with a

Commercial Due Diligence
Acquisition Financing

on the acquisition of GLOBOGATE concept AG

value not disclosed

Mai 2022
Icon: flag-ITIcon: flag-IT

goetzpartners advised

F2i SGR S.p.A. with a

Commercial Due Diligence

on the acquisition of Althea

value not disclosed

April 2022
Icon: flag-FRIcon: flag-IT

goetzpartners advised

LBO France Gestion SAS with a

Commercial Due Diligence

on the acquisition of Astidental di Sabbione S.p.A.

value not disclosed

August 2021
Icon: flag-ITIcon: flag-IT

goetzpartners advised

Itago SGR S.p.A. with a

Commercial Due Diligence

on the acquisition of Operamed S.r.l.

value not disclosed

Dezember 2020
Icon: flag-GBIcon: flag-IT

goetzpartners advised

Neuberger Berman AIFM Sarl with a

Commercial Due Diligence

on the acquisition of Bluvet S.r.l.

value not disclosed

Mai 2020
Icon: flag-FRIcon: flag-IT

goetzpartners advised

LBO France Gestion SAS with a

Commercial Due Diligence

goetzpartners advised LBO France Gestion SAS with a

value not disclosed

Februar 2020
Icon: flag-ITIcon: flag-IT

goetzpartners advised

Arcadia SGR S.p.A. with a

Commercial Due Diligence

on the acquisition of Favillini S.r.l. and Ideagrafica S.r.l.

value not disclosed

Mai 2019
Icon: flag-FRIcon: flag-IT

goetzpartners advised

ArchiMed SAS with a

Commercial Due Diligence

on the acquisition of DIESSE Diagnostica Senese S.p.A.

value not disclosed

April 2019
Icon: flag-ITIcon: flag-IT

goetzpartners advised

Alto Partners SGR S.p.A. with a

Commercial Due Diligence

on the acquisition of OFI Officina Italiana Farmaceutica S.p.A.

value not disclosed

Oktober 2018
Icon: flag-DEIcon: flag-DE

goetzpartners advised

Gimv on the

Commercial Due Diligence

in the acquisition of Medi-Markt GmbH

value not disclosed

Dezember 2017
Icon: flag-DEIcon: flag-DE

goetzpartners advised

Silverfleet Capital on the

Commercial Due Diligence

in the acquisition of 7days

value not disclosed

Dezember 2017
Icon: flag-DEIcon: flag-CH

goetzpartners advised

ECM Equity Capital Managementcon the

Commercial Due Diligence

in the acquisition of Uroviva Group

value not disclosed

Dezember 2016
Icon: flag-ITIcon: flag-IT

goetzpartners advised

Mandarin Capital Partners with a

Commercial Due Diligence

on the acquisition of Mipharm S.p.A.

value not disclosed

November 2016
Icon: flag-DEIcon: flag-DE

goetzpartners advised

ECM Equity Capital Management on the

Commercial Due Diligence

in the acquisition of Dermatologikum Hamburg

value not disclosed

November 2016
Icon: flag-DEIcon: flag-DE

goetzpartners advised

ARDIAN on the

Commercial Due Diligence

in the acquisition of Schwind eye-tech-solutions GmbH & Co. KG

value not disclosed